These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 1825816

  • 1. A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits.
    Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA.
    FASEB J; 1991 Mar 01; 5(3):338-43. PubMed ID: 1825816
    [Abstract] [Full Text] [Related]

  • 2. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia.
    Fischer E, Marano MA, Van Zee KJ, Rock CS, Hawes AS, Thompson WA, DeForge L, Kenney JS, Remick DG, Bloedow DC.
    J Clin Invest; 1992 May 01; 89(5):1551-7. PubMed ID: 1533231
    [Abstract] [Full Text] [Related]

  • 3. Interleukin-1 (IL-1) receptor antagonist prevents Staphylococcus epidermidis-induced hypotension and reduces circulating levels of tumor necrosis factor and IL-1 beta in rabbits.
    Aiura K, Gelfand JA, Burke JF, Thompson RC, Dinarello CA.
    Infect Immun; 1993 Aug 01; 61(8):3342-50. PubMed ID: 8335365
    [Abstract] [Full Text] [Related]

  • 4. Analysis of the inflammatory cytokine network among TNF alpha, IL-1 beta, IL-1 receptor antagonist, and IL-8 in LPS-induced rabbit arthritis.
    Matsukawa A, Yoshimura T, Miyamoto K, Ohkawara S, Yoshinaga M.
    Lab Invest; 1997 May 01; 76(5):629-38. PubMed ID: 9166282
    [Abstract] [Full Text] [Related]

  • 5. Enhancement of growth of virulent strains of Escherichia coli by interleukin-1.
    Porat R, Clark BD, Wolff SM, Dinarello CA.
    Science; 1991 Oct 18; 254(5030):430-2. PubMed ID: 1833820
    [Abstract] [Full Text] [Related]

  • 6. Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli.
    Wakabayashi G, Gelfand JA, Jung WK, Connolly RJ, Burke JF, Dinarello CA.
    J Clin Invest; 1991 Jun 18; 87(6):1925-35. PubMed ID: 2040686
    [Abstract] [Full Text] [Related]

  • 7. Maintenance of dynamic microvascular function and structure in a rat model of endotoxic shock by blockade of the interleukin-1 receptor.
    Norman JG, Sutton ET, Franz MS, Baker CH.
    Shock; 1995 May 18; 3(5):369-75. PubMed ID: 7648339
    [Abstract] [Full Text] [Related]

  • 8. Interleukin-1 induces a shock-like state in rabbits: synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.
    Dinarello CA, Okusawa S, Gelfand JA.
    Prog Clin Biol Res; 1989 May 18; 286():243-63. PubMed ID: 2494673
    [Abstract] [Full Text] [Related]

  • 9. Hematologic and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humans.
    Granowitz EV, Porat R, Mier JW, Orencole SF, Callahan MV, Cannon JG, Lynch EA, Ye K, Poutsiaka DD, Vannier E.
    Blood; 1993 Nov 15; 82(10):2985-90. PubMed ID: 8219190
    [Abstract] [Full Text] [Related]

  • 10. Production of interleukin-1-receptor antagonist during experimental endotoxaemia.
    Granowitz EV, Santos AA, Poutsiaka DD, Cannon JG, Wilmore DW, Wolff SM, Dinarello CA.
    Lancet; 1991 Dec 07; 338(8780):1423-4. PubMed ID: 1683422
    [Abstract] [Full Text] [Related]

  • 11. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.
    Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA.
    J Clin Invest; 1988 Apr 07; 81(4):1162-72. PubMed ID: 3258319
    [Abstract] [Full Text] [Related]

  • 12. Impact of continuous hemofiltration on cytokines and cytokine inhibitors in oliguric patients suffering from systemic inflammatory response syndrome.
    van Bommel EF, Hesse CJ, Jutte NH, Zietse R, Bruining HA, Weimar W.
    Ren Fail; 1997 May 07; 19(3):443-54. PubMed ID: 9154661
    [Abstract] [Full Text] [Related]

  • 13. Interleukin 1 induces HIV-1 expression in chronically infected U1 cells: blockade by interleukin 1 receptor antagonist and tumor necrosis factor binding protein type 1.
    Granowitz EV, Saget BM, Wang MZ, Dinarello CA, Skolnik PR.
    Mol Med; 1995 Sep 07; 1(6):667-77. PubMed ID: 8529133
    [Abstract] [Full Text] [Related]

  • 14. Host-tumor interaction in ovarian cancer. Spontaneous release of tumor necrosis factor and interleukin-1 inhibitors by purified cell populations from human ovarian carcinoma in vitro.
    Burger RA, Grosen EA, Ioli GR, Van Eden ME, Brightbill HD, Gatanaga M, DiSaia PJ, Granger GA, Gatanaga T.
    Gynecol Oncol; 1994 Nov 07; 55(2):294-303. PubMed ID: 7959299
    [Abstract] [Full Text] [Related]

  • 15. Interleukin-1 contributes to increased concentrations of soluble tumor necrosis factor receptor type I in sepsis.
    van der Poll T, Fischer E, Coyle SM, Van Zee KJ, Pribble JP, Stiles DM, Barie PS, Buurman WA, Moldawer LL, Lowry SF.
    J Infect Dis; 1995 Aug 07; 172(2):577-80. PubMed ID: 7622910
    [Abstract] [Full Text] [Related]

  • 16. Human neutrophils produce high levels of the interleukin 1 receptor antagonist in response to granulocyte/macrophage colony-stimulating factor and tumor necrosis factor alpha.
    McColl SR, Paquin R, Ménard C, Beaulieu AD.
    J Exp Med; 1992 Aug 01; 176(2):593-8. PubMed ID: 1386877
    [Abstract] [Full Text] [Related]

  • 17. Comparison of peripheral blood leukocyte kinetics after live Escherichia coli, endotoxin, or interleukin-1 alpha administration. Studies using a novel interleukin-1 receptor antagonist.
    Hawes AS, Fischer E, Marano MA, Van Zee KJ, Rock CS, Lowry SF, Calvano SE, Moldawer LL.
    Ann Surg; 1993 Jul 01; 218(1):79-90. PubMed ID: 8328833
    [Abstract] [Full Text] [Related]

  • 18. Potential hazards of combination immunotherapy in the treatment of experimental septic shock.
    Opal SM, Cross AS, Jhung JW, Young LD, Palardy JE, Parejo NA, Donsky C.
    J Infect Dis; 1996 Jun 01; 173(6):1415-21. PubMed ID: 8648214
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of granuloma formation induced by potassium permanganate in the mouse by a specific human recombinant receptor antagonist for interleukin-1 (hrIL-1ra).
    Conti P, Panara MR, Fridas S, Barbacane RC, Grilli A, Placido FC, Reale M, Fiore S.
    Cell Immunol; 1993 Apr 01; 147(2):446-57. PubMed ID: 8384086
    [Abstract] [Full Text] [Related]

  • 20. Human interleukin-1 receptor antagonist. High yield expression in E. coli and examination of cysteine residues.
    Steinkasserer A, Solari R, Mott HR, Aplin RT, Robinson CC, Willis AC, Sim RB.
    FEBS Lett; 1992 Sep 21; 310(1):63-5. PubMed ID: 1388125
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.